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Background: Female abdominal obesity is associated with hyperandrogenemia (HA), but few studies have addressed
the possible association between HA and metabolic syndrome (MetS) among obese women. Some studies indicate
that insulin resistance may cause HA through different mechanisms. On the other hand, a bidirectional relationship
between HA and insulin resistance has been suggested. Thus, we aimed to investigate if morbidly obese women with
HA had higher odds of MetS and its components than those without HA (controls), independent of polycystic ovarian
syndrome (PCOS) status.
Methods: This cross-sectional study comprised 1900 consecutive treatment seeking morbidly obese women <50 years. Free
testosterone index (FTI) >0.6 defined HA. Women with previously diagnosed PCOS and those with oligo- / anovulation
combined with clinical or biochemical hyperandrogenism were defined as having PCOS. Multiadjusted associations between
HA and MetS were assessed by logistic regression analysis.
Results: Out of 1900 morbidly obese women, 1089 (57 %), 846 (45 %) and 312 (16 %) had MetS, HA and PCOS, respectively.
Compared with controls (without HA), women with HA were younger (34 [1] years vs. 39 [2], p< 0.001) had a higher
prevalence of MetS (62 % vs. 53 %, p < 0.001), type 2 diabetes (18 % vs. 15 %, p = 0.045), low HDL-cholesterol
(65 % vs. 48 %, p < 0.001) and hypertriglyceridemia (48 % vs. 41 %, p = 0.004), but a lower prevalence of raised
blood pressure (53 % vs. 59 %, p = 0.014). Multivariable analyses showed that HA was associated with increased
odds of MetS (OR 1.61 [95 % CI 1.27, 2.02]), dysglycemia (1.65 [1.28, 2.11]), low HDL-cholesterol (1.58 [1.27, 1.97]),
and hypertriglyceridemia (1.43 [1.15, 1.79]). After stratification for the presence of PCOS, the results remained
largely unchanged in women without PCOS; MetS (1.52 [1.18, 1.96), dysglycemia (1.71 [1.30, 2.25]), low
HDL-cholesterol (1.55 [1.22, 1.98]) and hypertriglyceridemia (1.36 [1.06, 1.74]).
Conclusion: Morbidly obese women with HA had an approximately 1.5-fold increased odds of having MetS even
in the absence of PCOS. Randomized controlled clinical trials, including therapeutic strategies to lower free
testosterone levels, are however necessary to explore any cause-and-effect relationship.
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The polycystic ovarian syndrome (PCOS) is the most
common female endocrinopathy, affecting 8 – 12 % of
women of reproductive age [1], and 10–35 % of obese
women [2–4]. PCOS is associated with infertility, hyper-
androgenemia, impaired glucose tolerance and type 2 dia-
betes [5]. A combination of increased levels of androgens
and insulin is believed to contribute to the pathophysiology
of PCOS [5]. Hyperandrogenemia (HA) comprises the bio-
chemical hallmark of PCOS with elevated free testosterone
levels accounting for the majority of the abnormal labora-
tory findings in women with oligomenorrhea [6].
Excess body weight is associated with HA [7]. Further-
more, the hyperinsulinemia in obese women may dir-
ectly increase free testosterone levels by lowering the sex
hormone binding globulin synthesis in the liver [8]. On
the other hand, rodent models have shown that HA
promotes insulin resistance, reduces energy expenditure
and, accordingly, increases the risk of abdominal obesity
and metabolic risk factors [9, 10]. In a multiethnic sample
of more than 2500 U.S. women between 42 and 52 years
of age, oligomenorrhea was associated with the metabolic
syndrome (MetS) only when coincident with HA [11].
Conversely, women with HA had a significantly increased
risk of the MetS independent of the menstrual frequency
status [11].
The ovaries’ response to luteinizing hormone (LH) is
the main source of increased androgens in PCOS [12].
Also, the elevated response of adrenal steroids in
women with PCOS sustained only with adrenal stimu-
lation of ACTH, suggesting a secondary effect of in-
creased adrenal androgen production rather than
adrenal congenital enzyme deficit [13].
It is not clear how HA may affect cardiovascular dis-
ease. Abdominal obese women with PCOS are consid-
ered at high risk of cardiovascular disease, and a positive
association between coronary artery disease and clinical
hyperandrogenism (hirsutism and acne) has been re-
ported [14]. On the other hand, a population based
study showed that premenopausal overweight women
with PCOS did not have a higher risk of coronary artery
disease than those without PCOS [15]. Nevertheless,
women with PCOS and HA have a higher prevalence of
obesity and adverse metabolic abnormalities compared
to those without HA [16]. To the best of our knowledge,
no previous study has assessed the impact of HA on the
MetS independent of the presence or absence of PCOS
among obese women.
The primary aim of this study was to examine whether
treatment seeking premenopausal morbidly obese women
with HA had higher odds for MetS and its components
(low HDL-cholesterol, hypertriglyceridemia, raised blood
pressure, and dysglycemia) than women without HA,
independent of PCOS status.Methods
Design and study population
A total of 2681 consecutive treatment seeking morbidly
obese women attending the Morbid Obesity Centre at
Vestfold Hospital Trust, Norway, during the period from
November 28th 2005 until July 28th 2014 were assessed
for eligibility. To avoid biological bias of including both
pre- and postmenopausal women, we excluded 743
women ≥50 years [17–19]. Data on HA were missing
for 38 women (PCOS absent n = 34 and PCOS present
n = 4), leaving 1900 morbidly obese women of repro-
ductive age to be included in this cross-sectional
analysis. The study was approved by the Regional
Committee for Medical and Health Research Ethics
(S-05175). The participants were included after pro-
viding written informed consent, and the study was
performed in accordance with the Declaration of
Helsinki [20].Definitions
We defined MetS according to the joint interim state-
ment of the International Diabetes Federation Task
Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association;
World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of
Obesity (2009); if WC ≥ 80 cm combined with a mini-
mum of two out of four criteria present: 1) low HDL-
cholesterol; HDL-cholesterol <1.3 mmol/L, 2) hypertri-
glyceridemia; triglycerides ≥1.7 mmol/L, 3) raised blood
pressure; systolic blood pressure ≥130 mmHg or dia-
stolic blood pressure ≥85 mmHg, or use of blood pres-
sure lowering medication, and 4) dysglycemia; fasting
serum glucose ≥5.6 mmol/L or diabetes mellitus [21].
Type 2 diabetes was diagnosed in patients who had a
prior history of type 2 diabetes or a fasting plasma glu-
cose ≥7.0 mmol/L or an HbA1c ≥6.5 %. The Homeosta-
sis Model Assessment Insulin Resistance (HOMA IR)
was calculated as ([fasting serum glucose (mmol/l) *
fasting serum insulin (pmol/l)]/135) [22]. We calculated
the free testosterone index (FTI) using the formula:
FTI = 100 x serum testosterone (nmol/L) / sex hor-
mone binding globulin (SHBG, nmol/L). Free testoster-
one was calculated from the formula described by
Vermeulen et al. [23]. According to the Androgen Ex-
cess & PCOS Society consensus statement on PCOS
diagnosis, HA is defined by increased levels of free
testosterone [6, 24]. Accordingly, women with an FTI
above the upper normal range (FTI > 0.6) were defined
as having HA [25]. Women with previously diagnosed
PCOS and those with an FTI > 0.6 or hirsutism com-
bined with oligo- / anovulation were defined as having
PCOS [16, 26].
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Patients had their weight and height measured wearing
light clothing, without shoes, and BMI was subse-
quently calculated (kg/m2). We measured WC midway
between the lowest rib margin and the iliac crest.
Blood pressure was measured with an appropriate cuff
after at least 5 minutes rest with the patient seated in
an upright position. Three measurements were regis-
tered and the average of the second and the third
measurement was used in the study. All anthropomet-
ric and blood pressure measurements were performed
by trained study personnel.Laboratory analysis
Blood samples were obtained by venipuncture after an
overnight fast and collected in Vacutainers® gel tubes.
Serum was separated from cells within two hours.
Analyses of serum glucose, magnesium, uric acid,
and blood lipids were performed using dry reagent
slide technology on the Vitros 950 Analyzer until No-
vember 2006 and thereafter on the Vitros FS 5.1 (Or-
tho-Clinical Diagnostics, New York, USA). Intact PTH
was measured using an electro-chemiluminescence
immunoassay on the Elecsys 2010 (Roche Diagnostics
GmbH) or Architect i1000SR (Abbott Diagnostics).
The results of the electro-chemiluminescence im-
munoassay were multiplied by a conversion factor of
1.34 [27]. Glycosylated hemoglobin was analyzed by
high performance liquid chromatography (HPLC)
using Tosoh HLC-723 G7 (Tosoh Corporation, Tokyo,
Japan). All other analyses were performed on the day
of blood sampling at the Department of Clinical
Chemistry at Vestfold Hospital Trust. Sera for analysis
of insulin, testosterone, SHBG and 25(OH) vitamin D
(25-hydroxyvitamin D2 + 25-hydroxyvitamin D3) were
stored at −20 °C and analyzed within one week of
blood sampling at the Hormone Laboratory, Oslo Uni-
versity Hospital, Aker. Insulin and 25(OH) vitamin D
were analyzed in serum by radioimmunoassay (Linco
Research Inc, St Charles, MO, and DiaSorin, Stillwater,
MN). The interassay coefficients of variation (CV) for
insulin and 25 (OH) vitamin D were 8 % and 14 %,
respectively. Testosterone was measured in serum by
a competitive radioimmunoassay (RIA) technique
using 125I testosterone (Orion Diagnostica, Espoo,
Finland) with a coefficient of variance (CV) at the
lower normal reference interval (mean 2.2 nmol/L) of
11 %. Samples with a testosterone concentration
level ≥ 4 nmol/L were checked for interference after
ether extraction. SHBG in serum was measured by
immunoluminometric assay (ILMA) (Immunlite 2000
or 2500, Siemens, NY, US, Healthcare Diagnostics)
with a CV of 6 %.Statistical analysis
Data are presented as mean (SD) or proportions.
Continuous and categorical variables were compared
using independent samples t-test and χ2 test or Fisher’s
exact test as appropriate. Correlations were calcu-
lated with Pearson’s correlations coefficient (r) for
normally distributed variables and Spearman’s Rho
(ρ) for non-normally distributed variables. Demo-
graphic, anthropometric and metabolic variables
were analyzed including the whole study population
and after stratification for presence or absence of
PCOS.
The MetS and its components were modeled as
dependent variables and HA as the primary explana-
tory variable. The association between HA and MetS
was adjusted for significant confounders identified
using a backward logistic regression approach. Vari-
ables with p-values below 0.10 were included in the
final model (Wald test). Consequently, coronary ar-
tery disease (yes/no), prednisolone usage (yes/no),
chronic obstructive pulmonary disease (yes/no), joint
pain (yes/no), use of estrogens or gestagen medica-
tion (yes/no), and thyroid stimulating hormone were
removed from the regression model. The models
were adjusted for the following covariates in the final
multivariable analysis: age (years), family history of
diabetes (yes/no), uric acid (μmol/L), anxiety or de-
pression (yes/no), cholelithiasis (yes/no), history of
smoking (current or former/never), physical activity
(≥1 hour vigorously physical activity/week), parathy-
roid hormone (pmol/L), and vitamin D-25-OH
(nmol/L). We decided not to adjust for WC and
HOMA IR in order to avoid the possibility of over-
adjustment bias by variables known to be in the
causal pathway between HA and the MetS [10, 28].
Univariate and multivariate logistic regression
models were used to assess the associations between
HA and MetS and its components (hypertriglyc-
eridemia, low HDL-cholesterol, raised blood pres-
sure, and dysglycemia) in all the 1900 included
patients. In addition, the analyses were repeated in a
subgroup of obese women without PCOS and an-
other group with PCOS, respectively. Possible effect
modifications by age and PCOS were investigated by
including the products age*HA, and PCOS*HA as
interaction terms in the multivariable analyses with
MetS as the dependent variable.
The goodness of fit was tested using the Hosmer
and Lemeshow test. P-values below 0.05 were consid-
ered statistically significant. However, due to the
considerable number of statistical tests performed,
particular attention should be directed towards
smaller P-values, i.e. those below 0.01. The analyses
were implemented using IBM SPSS statistics 20.
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A total of 1089 (57 %), 846 (45 %) and 312 (16 %) out of
1900 morbidly obese women under 50 years of age
(mean age 37 [SD 8] years) had MetS, HA and PCOS,
respectively. A total of 1445 women had either the
metabolic syndrome (MetS), hyperandrogenemia (HA)
or polycystic ovarian syndrome (PCOS), whereas 455
women had neither MetS, HA or PCOS. The overlap of
women with MetS, HA and PCOS is presented in Fig. 1.
In the whole study population, women with HA were
younger (mean [SD] age 34 [1] vs. 39 [2] years, p < 0.001),
heavier [body weight 125 [19] vs. 121 [18] kg, p < 0.001),
had a higher WC (127 [13] vs. 123 [13] cm, p < 0.001), and
were more insulin resistant than the women without HA
(HOMA IR; 5.8 [5.5] vs. 4.5 [4.3], p < 0.001). The HA
group had a significantly higher prevalence of MetS (62 %
vs. 53 %, p < 0.001), PCOS (27 % vs. 8 %, p < 0.001) and
were more likely to have low HDL-cholesterol (65 % vs.
48 %, p < 0.001), hypertriglyceridemia (48 % vs. 41 %, p =
0.004) and type 2 diabetes (18 % vs. 15 %, p = 0.045).
Women with HA had a lower prevalence of raised blood
pressure (53 % vs. 59 %, p = 0.014) and were less likely
to use blood pressure lowering medication (18 % vs.
25 %, p < 0.001). A tendency towards a higher preva-
lence of dysglycemia was seen in women with HA com-
pared to women without HA (32 % vs. 28 %, p = 0.069).
The demographic, anthropometric and metabolic dif-
ferences between participants with and without HA did
not change substantially after stratification according toFig. 1 The figure shows the overlap between the 1445 women characteriz
syndrome and hyperandrogenemia (HA). Women without any of these conpresence or absence of PCOS (Table 1). The prevalence
of MetS was higher in women with HA than in women
without HA independent of the presence or absence of
PCOS (PCOS absent: 60 % vs. 53 %, p = 0.007 and PCOS
present: 68 % vs. 55 %, p = 0.032).
The proportion of women with HA decreased from
80 % (<20 years) to 30 % (40–50 years) with increasing
age deciles (Fig. 2). By contrast, the percentages of
women with MetS, dysglycemia, hypertriglyceridemia
and raised blood pressure increased significantly with
age (all p < 0.001) (Fig. 2). The proportion of women
with low HDL-cholesterol did, however, not change
significantly with age (p = 0.145).
The FTI correlated weakly with HDL-cholesterol,
systolic blood pressure and diastolic blood pressure (r =
0.10, p < 0.001; r = −0.05, p = 0.040; and r = −0.06, p =
0.007) and HOMA IR (ρ = 0.22, p < 0.001), but not with
BMI, WC, triglycerides and fasting plasma glucose (r =
0.04; r = 0.03; r = 0.03; r = −0.01, all p > 0.111). We did
not find any significant interactions between HA and
age (p = 0.834) or between HA and PCOS (p = 0.527).
In the univariate analysis, HA was associated with a 1.5
fold increased odds of MetS (OR 1.45 [95 % CI 1.20,
1.74]). This association remained statistically significant
after adjustments for possible confounders (1.61 [1.27,
2.02]) (Table 2 and Fig. 3A). Moreover, HA was associated
with approximately 1.5 fold increased adjusted odds of
dysglycemia (1.65 [1.28, 2.11]), low HDL-cholesterol (1.58
[1.27, 1.97]), and hypertriglyceridemia (1.43 [1.15, 1.79]).ed by their having the metabolic syndrome, polycystic ovarian
ditions (n = 455) were not included in Fig. 1
Table 1 Patient characteristic according to presence or absence of polycystic ovarian syndrome (PCOS) and hyperandrogenemia (HA)
PCOS absent PCOS present
HA present HA absent P value HA present HA absent P value
N 616 972 - 230 82 -
Age, yrs 35 (8) 39 (7) <0.001 33 (8) 36 (8) 0.001
BMI, kg/m2 44.4 (5.8) 43.2 (5.9) <0.001 44.8 (6.4) 42.8 (6.2) 0.015
Weight, kg 124 (18) 121 (18) <0.001 126 (20) 119 (19) 0.016
Waist circumference, cm 127 (13) 123 (13) <0.001 127 (14) 123 (13) 0.025
WHR 0.94 (0.09) 0.92 (0.08) <0.001 0.94 (0.08) 0.93 (0.10) 0.384
Metabolic syndrome 370 (60 %) 517 (53 %) 0.008 157 (68 %) 45 (55 %) 0.032
-waist≥ 80 cm 611 (100 %) 963 (100 %) 1.000 228 (100 %) 82 (100 %) -
-lipids 457 (74 %) 633 (65 %) <0.001 186 (81 %) 51 (62 %) 0.001
triglycerides ≥1.7 mmol/L 285 (46 %) 398 (41 %) 0.037 116 (50 %) 32 (39 %) 0.094
HDL-cholesterol <1.30 mmol/L 391 (64 %) 469 (49 %) <0.001 160 (70 %) 41 (50 %) 0.002
lipid lowering medication 37 (6 %) 66 (7 %) 0.601 18 (8 %) 8 (10 %) 0.642
-raised blood pressure 320 (52 %) 570 (59 %) 0.007 131 (57 %) 50 (61 %) 0.603
Systolic blood pressure ≥130, mmHg 233 (38 %) 386 (40 %) 0.428 106 (47 %) 36 (44 %) 0.700
Diastolic blood pressure≥ 85, mmHg 195 (32 %) 311 (32 %) 0.868 74 (33 %) 28 (34 %) 0.785
Blood pressure lowering medication 110 (18 %) 246 (25 %) 0.001 44 (19 %) 17 (21 %) 0.748
-fasting plasma glucose≥ 5.6 mmol/L OR diabetes mellitus 192 (31 %) 270 (28 %) 0.157 77 (34 %) 23 (28 %) 0.410
Type 2 diabetes 112 (18 %) 143 (15 %) 0.069 42 (18 %) 12 (15 %) 0.501
Cholelithiasis 59 (10 %) 114 (12 %) 0.187 18 (8 %) 7 (9 %) 0.816
Family history diabetes 195 (32 %) 300 (31 %) 0.781 87 (38 %) 30 (37 %) 0.895
Systolic blood pressure, mmHg 125 (15) 126 (14) 0.290 127 (14) 128 (16) 0.806
Diastolic blood pressure, mmHg 80 (10) 80 (10) 0.394 80 (10) 80 (10) 0.516
Uric acid, μmol/L 345 (69) 325 (69) <0.001 358 (69) 325 (72) <0.001
PTH, pmol/L 6.9 (2.9) 7.2 (3.3) 0.045 6.7 (3.0) 7.3 (2.9) 0.147
Vitamin D 25-OH, nmol/L 54 (21) 57 (21) 0.006 49 (19) 50 (18) 0.840
Magnesium 0.84 (0.07) 0.85 (0.07) 0.178 0.83 (0.07) 0.83 (0.07) 0.978
Anxiety or depression 290 (47 %) 446 (46 %) 0.643 122 (53 %) 38 (46 %) 0.306
Insulin, pmol/L 129 (95) 107 (83) <0.001 142 (75) 118 (70) 0.012
HOMA IR, (mmol/l * pmol/L / 135) 5.7 (6.0) 4.5 (4.4) <0.001 6.0 (3.9) 4.8 (3.4) 0.017
≥1 hour physical activity/week 329 (64 %) 549 (67 %) 0.238 126 (68 %) 44 (60 %) 0.246
≥1 hour vigorous physical activity/week 192 (37 %) 356 (43 %) 0.026 73 (40 %) 32 (44 %) 0.574
Use of estrogens or gestagen medication 62 (10 %) 112 (12 %) 0.410 15 (7 %) 20 (24 %) <0.001
Smoke (current or former/never) 368 (60 %) 561 (58 %) 0.432 147 (64 %) 38 (46 %) 0.006
SHBG, nmol/L 22.3 (9.2) 44.3 (29.2) <0.001 20.8 (8.1) 46.6 (30.3) <0.001
Total testosterone, nmol/L 1.90 (0.71) 1.16 (0.55) <0.001 2.3 (1.2) 1.3 (0.5) <0.001
Estimated free testosterone, nmol/L 0.039 (0.085) 0.003 (0.005) <0.001 0.056 (0.140) 0.003 (0.005) 0.001
FTI 1.3 (3.1) 0.3 (0.1) <0.001 1.7 (5.2) 0.3 (0.1) 0.017
BMI; body mass index. WHR; waist hip ratio. PTH; parathyroid hormone. PCOS; polycystic ovarian syndrome. HOMA IR; Homeostasis Model Assessment - Insulin
Resistance. FTI; free testosterone index, FTI > 0.6; Hyperandrogenemia (HA). SHBG; sex hormone binding globulin
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[0.85, 1.34]). A sub-analysis of 1588 women without PCOS
showed that HA remained significantly associated with
MetS (OR 1.52 [95 % CI 1.18, 1.96), dysglycemia (1.71[1.30, 2.25]), low HDL-cholesterol (1.55 [1.22, 1.98]) and
hypertriglyceridemia (1.36 [1.06, 1.74]) (Fig. 3B). In con-
trast, HA was neither significantly associated with MetS,
nor its components in women with PCOS (Fig. 3C).
Fig. 2 The figure shows the proportion of morbidly obese women with hyperandrogenemia (HA), the metabolic syndrome (MetS) and its components
according to various age categories. The prevalence of HA decreased, while the proportions of patients with MetS, dysglycemia, hypertriglyceridemia
and raised blood pressure increased significantly with increasing age (* p < 0.001). The proportion of women with low HDL-cholesterol did, not change
significantly with age (p = 0.145)
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The main and novel finding of this study of premenopausal
white morbidly obese women, was that HA was associated
with 61 % increased adjusted odds of MetS, and that this
association was mainly driven by increased odds of dysgly-
cemia and dyslipidemia. Although the prevalence of HA
decreased, while the prevalence of MetS increased with
increasing age, HA remained an independent predictor of
MetS and its components, dysglycemia and dyslipidemia.
Hyperandrogenemia and the metabolic syndrome
The results of the present study cohere with another
cross-sectional study of 2543 multiethnic overweightTable 2 The odds of the metabolic syndrome (MetS) and its compo
Metabolic syndrome Dysglycemi
OR 95 % CI OR 95 %
Age, yrs 1.06 1.04, 1.07 1.09 1.07, 1
Family history diabetes 1.41 1.12, 1.77 1.51 1.19, 1
Uric acid, μmol/L 1.01 1.00, 1.01 1.00 1.00, 1
Cholelithiasis 1.52 1.05, 2.21 1.25 0.87, 1
≥ 1 hour vigorous physical activity/week 0.91 0.73, 1.13 0.95 0.75, 1
Vitamin D-25-OH, nmol/L 0.99 0.98, 0.99 0.99 0.98, 0
PTH, pmol/L 0.98 0.96, 1.01 0.98 0.96, 1
Anxiety or depression 1.33 1.08, 1.65 1.43 1.13, 1
Smoke (current or former/never) 1.45 1.17, 1.79 1.17 0.92, 1
HA, FTI >0.6 (yes/no) 1.61 1.27, 2.02 1.65 1.28, 2
Dependent variables; metabolic syndrome and its components. Hypertriglyceridem
mmol/L, dysglycemia; fasting glucose ≥5.6 mmol/L or established diabetes mellitus
pressure ≥85 mmHg or use of blood pressure lowering medication. PTH; Parathyroi
testosterone indexpre- and perimenopausal women who were on average
age ten years older than the participants in the present
study (46 vs. 37 years, respectively) [11]. In the previ-
ous study, women with HA, regardless of menstrual
cycles, had a 1.5 fold increased risk of MetS compared
to those without HA [11]. Women with both oligo-
menorrhea and HA had a 2 fold increased odds of
MetS [11]. In our sub-analysis of 1588 severely obese
women without PCOS, HA remained a significant pre-
dictor of MetS, dysglycemia, low HDL-cholesterol, and
hypertriglyceridemia. In contrast, no association be-
tween androgen excess, menstrual irregularity and in-
cident MetS or self-reported cardiovascular diseasenents adjusted for possible confounders.
a Low HDL-cholesterol Hypertriglyceridemia Raised blood pressure
CI OR 95 % CI OR 95 % CI OR 95 % CI
.11 1.00 0.98, 1.01 1.03 1.02, 1.05 1.08 1.07, 1.10
.92 1.24 0.99, 1.54 1.20 0.96, 1.49 1.36 1.09, 1.71
.00 1.00 1.00, 1.01 1.01 1.00, 1.01 1.00 1.00, 1.00
.80 1.16 0.82, 1.64 1.27 0.90, 1.79 1.24 0.87, 1.78
.20 1.01 0.82,1.25 0.81 0.66, 1.00 0.99 0.80, 1.23
.99 0.99 0.98, 0.99 1.00 0.99, 1.00 0.99 0.99, 1.00
.01 0.96 0.94, 0.99 0.97 0.95, 1.00 1.01 0.98, 1.04
.80 1.22 0.99, 1.50 1.53 1.24, 1.89 0.91 0.73, 1.12
.48 1.38 1.12, 1.70 1.40 1.13, 1.73 0.97 0.78, 1.20
.11 1.58 1.27, 1.97 1.43 1.15, 1.79 1.06 0.85, 1.34
ia; triglycerides; ≥1.7 mmol/L, low HDL-cholesterol; HDL-cholesterol , <1.3
, raised blood pressure; systolic blood pressure ≥130 mmHg or diastolic blood
d hormone. FTI; free testosterone index. HA; hyperandrogenemia. FTI; free
Fig. 3 (See legend on next page.)
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Fig. 3 The figure shows the multivariable odds ratios with 95 % confidence intervals (OR [95 % CI]) for metabolic syndrome (MetS) and its components
in morbidly obese women with hyperandrogenemia compared to women without hyperandrogenemia (HA) (reference). Panel A comprises all the
women included in the study (n= 1900), whereas Panel B and C comprises women included in the sub-analyses; PCOS absent (n = 1588) and PCOS
present (n = 312)
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women [28].Possible mechanisms linking hyperandrogenemia to
insulin resistance and visceral obesity
Animal (rodent) studies indicate that androgens may
produce insulin resistance by direct effects on skeletal
muscle and adipose tissue, mediated by alterations in the
insulin receptor –glycogen synthesis, by altering adipo-
kine secretion, and by increasing visceral adiposity [9].
Moreover, a small study of 13 obese and 30 non-obese
women showed that anti-androgen treatment partly re-
versed the peripheral insulin resistance in non-obese
women only, whereas central obesity may have a direct
role in androgen hypersecretion [29, 30]. Also, a recent
study of young, overweight women suggested that the
association between body fat and HA was predominantly
mediated by insulin resistance [24]. The interrelation-
ships between body fat, insulin resistance and HA con-
tribute to the complex pattern making it a difficult task
to specify the role of each component. Although the
findings by Tosi et al. may not be directly comparable
with ours, we also report a weak, but significant correl-
ation between insulin resistance and HOMA IR and FTI.
Acordingly, although HA was independently associated
with MetS, insulin resistance might partly have mediated
this effect.Association between hyperandrogenemia and
dyslipidemia
Our study demonstrated a significant inverse relation-
ship between HA and HDL-cholesterol levels which is
in accordance with previous studies of women with
PCOS [31, 32]. Reduced HDL-cholesterol levels have
also been reported in peri- and postmenopausal
women receiving androgen formulations added to hor-
mone replacement therapy and after transdermal tes-
tosterone treatment [33, 34]. Furthermore, low levels
of SHBG in women with PCOS have been associated
with low levels of HDL-cholesterol, independent of in-
sulin resistance and obesity [35]. Conversely, a recent
study of young overweight women showed no differ-
ences in dyslipidemia in women with HA compared to
women without HA [24]. Thus, the impact of HA on
dyslipidemia remains unclear and further research is
warranted.Hyperandrogenemia and dysglycemia
The proportion of women with HA decreased, whereas
the proportion of women with dysglycemia increased
with age (Fig. 2). Nevertheless, we found a significant
association between HA and dysglycemia independent of
age.
Studies have shown a high conversion rate from im-
paired glucose tolerance to diabetes mellitus in women
with PCOS [36, 37]. Our findings demonstrated that
women with and without PCOS had a comparable
prevalence of dysglycemia. However, patients with HA
had approximately 65 % increased odds of dysglycemia
compared to those without HA, and the association was
strengthened after the exclusion of women with PCOS.
These findings support the hypothesis that HA may be
involved in the pathophysiology of dysglycemia inde-
pendent of PCOS status.
Hyperandrogenemia and blood pressure
We did not find any significant association between HA
and raised blood pressure. This is in contrast with the
results from a study of young normal to overweight
Asian women with PCOS which demonstrated that high
bioavailable testosterone levels were associated with ele-
vated blood pressure [38]. In another study of middle
aged normal- to overweight women, facial hirsutism was
associated with higher systolic blood pressure, whereas
limb-hirsutism was associated with lower diastolic blood
pressure [39]. In the present study, premenopausal mor-
bidly obese women with HA were actually less likely to
use blood pressure lowering medication compared to
the women without HA (18 % vs. 25 %). Interestingly, a
recently published cross-sectional study of normal- to
overweight Swedish men and women showed a strong
inverse association between blood pressure and SHBG
while free testosterone concentration was not associated
with hypertension [40]. The authors speculated that
SHBG might have a direct effect on the endothelial cells
through the receptor for SHBG, but this association was
significant only in postmenopausal women ≥50 years of
age [40]. In contrast, our study did not demonstrate any
association between SHBG and raised blood pressure in
premenopausal women (data not shown).
Strengths and limitations
The major strength of the present study is the large cohort
of consecutively included treatment seeking morbidly obese
women. The study participants were, however, referred to a
Valderhaug et al. Diabetology & Metabolic Syndrome  (2015) 7:46 Page 9 of 10tertiary care center for evaluation and treatment with
bariatric surgery, medical therapy or long term lifestyle
rehabilitation for morbid obesity. Accordingly, the re-
sults cannot be generalized to the general obese popu-
lation (i.e. non-treatment seeking subjects).
We used an immunoassay to measure testosterone.
Although conventional immunoassays measure reliable
testosterone at high levels, the immunoassays have been
reported to be less reliable at low concentrations [41].
However, the separation procedure of diethyl extraction
was performed manually and should thus have reduced
the number of falsely elevated results.
Furthermore, although we defined FTI >0.6 as HA in
the present study, other adrenocortical precursor steroids
including pregnenolone, 17-hydroxypregnenolone, dehy-
droepiandrosterone (DHEA), androstenedione, 11-deoxy-
cortisol and cortisol may have contributed to clinical
manifestations of HA. Nevertheless, free testosterone
levels remain the predominant laboratory finding in
women with oligomenorrhea and the ovaries are the main
source of androgen excess in women with and without
PCOS [6, 12].
Unfortunately, we did not have precise menopause
data. There is some evidence that a higher BMI might
cause a later menopause. One study reported that obese
women (BMI ≥30 kg/m2) had a median age at meno-
pause of 53 years [17]. Consequently, by excluding
women over 50 years of age, some morbidly obese pre-
menopausal women might have been left out of our
analysis.
Finally, the majority (97 %) of the morbidly obese
women were Caucasian, and as such the results of might
not be applicable to women of other ethnicities.
Conclusion
In this study, the prevalences of MetS, PCOS and HA
were high among morbidly obese women <50 years of
age. Compared to women without HA, those with HA
had significantly higher odds of having the MetS, which
was mainly explained by the associations between HA
and the lipid- and glucose components of the MetS. Our
results, if confirmed, suggest that an FTI-blood test
might add value to the cardiovascular risk assessment of
premenopausal women with morbid obesity. Random-
ized controlled clinical trials, including therapeutic strat-
egies to lower free testosterone levels, are however
necessary to explore any cause-and-effect relationship.
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